SCHEMBL21963566

SCHEMBL21963566

O=C(Nc1cc(F)ccn1)C1CC1

nearest known ligand 0.61

Predicted protein targets (top 13)

geneUniProtsupporting neighboursconfidence
ACVRL1 P37023 3/20 0.61
GSK3B P49841 11/20 0.57
GSK3A P49840 2/20 0.56
MAPK14 Q16539 4/20 0.56
PIK3C3 Q8NEB9 3/20 0.56
MAPK8 P45983 2/20 0.55
MAPK10 P53779 2/20 0.55
JAK2 O60674 1/20 0.53
JAK1 P23458 1/20 0.53
TYK2 P29597 1/20 0.53
CDK9 P50750 1/20 0.53
JAK3 P52333 1/20 0.53
MAPT P10636 1/20 0.53

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31521720 1.00 ACVRL1 (0.61) ACVRL1GSK3BGSK3AMAPK14PIK3C3
SCHEMBL27873522 0.81 ACVRL1 (0.63) ACVRL1GSK3BGSK3AMAPK14PIK3C3
SCHEMBL15542541 0.81 ACVRL1 (0.63) ACVRL1GSK3BGSK3APIK3C3JAK2
SCHEMBL17539612 0.80 ACVRL1 (0.62) ACVRL1GSK3BGSK3APIK3C3JAK2
SCHEMBL15542212 0.80 ABL1 (0.62) ACVRL1GSK3BGSK3APIK3C3JAK2
SCHEMBL29366775 0.80 ACVRL1 (0.62) ACVRL1GSK3BGSK3APIK3C3JAK2
SCHEMBL10352589 0.80 ACVRL1 (0.61) ACVRL1GSK3BPIK3C3MAPT
SCHEMBL22659338 0.80 ACVRL1 (0.66) ACVRL1GSK3BGSK3APIK3C3JAK2
SCHEMBL17377666 0.80 ACVRL1 (0.61) ACVRL1GSK3BPIK3C3JAK2JAK1
SCHEMBL24932207 0.80 KDR (0.63)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3880671-B1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO N CORP (KR) 2025-03-12 EP disclosed
US-12180185-B2 Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof HK INNO.N CORPORATION (KR) 2024-12-31 US disclosed
US-20220009902-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO.N CORPORATION (KR) 2022-01-13 US disclosed
US-20220009902-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO.N CORPORATION (KR) 2022-01-13 US disclosed
EP-3880671-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK inno.N Corporation (KR) 2021-09-22 EP disclosed
CN-113166094-A Novel compounds as protein kinase inhibitors and pharmaceutical compositions comprising the same 怡诺安有限公司 2021-07-23 CN disclosed
WO-2020101382-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO.N CORPORATION (KR) 2020-05-22 WO disclosed
WO-2020101382-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF HK INNO.N CORPORATION (KR) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12180185-B2 Compound as protein kinase inhibitor, and pharmaceutical composition comprising thereof MAP3K20, MAP3K1, MAP3K15 ACVRL1 4032/4885GSK3B 181/4885GSK3A 172/4885
US-20220009902-A1 NOVEL COMPOUND AS PROTEIN KINASE INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING THEREOF MAP3K20, MAP3K1, MAP3K15 ACVRL1 3860/4885GSK3B 231/4885GSK3A 220/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.